|
Polyendocrinopathies, Autoimmune
|
0.100 |
Biomarker
|
group |
BEFREE |
Prothrombin fragment F1 + 2 (F1 + 2) and thrombin-antithrombin (TAT) have been assessed in antiphospholipid syndrome (APS) but without evaluating a direct relationship with antiphospholipid (aPL) antibody titers.
|
31234212 |
2019 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
Biomarker
|
group |
BEFREE |
Phosphatidylserine/Prothrombin complex antibody (aPSPT) though associated with various APS manifestations, is not included in the revised Sapporo Criteria.
|
30255283 |
2019 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
Biomarker
|
group |
BEFREE |
Current recommendations advocate for the use of anti-Xa activity monitoring in the setting of APS because of the common laboratory interaction with commercially available tests, such as prothrombin and activated partial thromboplastin times .
|
31090599 |
2019 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
Biomarker
|
group |
BEFREE |
Prothrombin conversion was significantly increased in nontreated APS patients.
|
29895622 |
2018 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
Biomarker
|
group |
BEFREE |
Sera from 61 obstetrical seronegative APS (SN-APS) patients were analyzed for anti-cardiolipin antibodies (aCL) using thin-layer chromatography (TLC)-immunostaining, for anti-cardiolipin/vimentin antibodies (aCL/Vim), anti-phosphatidylserine/prothrombin antibodies, IgA anti-β<sub>2</sub>glycoprotein I antibodies (aβ<sub>2</sub>GPI), and IgA aCL antibodies by enzyme-linked immunosorbent assay.
|
30079071 |
2018 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we evaluated the clinical relevance of antibodies to prothrombin (PT) (aPT) and thrombin (aThr) in Chinese patients with APS.
|
27807637 |
2017 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There were no differences in the prevalence of recurrent thrombosis before or after APS diagnosis in patients with or without prothrombin gene polymorphism.
|
24093662 |
2014 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the various aPL (anticardiolipin antibodies, lupus anticoagulant, anti-beta2GPI antibodies, antiphosphatidylserine/prothrombin antibodies) show similar HLA association, again independent of the clinical context (primary APS or SLE), and across various ethnic groups.
|
14550881 |
2003 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The prevalence of FVL was similar to that found in the control group whereas PT-20210A was significantly more frequent in APS patients than in normal controls (2.0%, p=0.02).
|
11454529 |
2001 |
|
Polyendocrinopathies, Autoimmune
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Heterozygous PT G20210A contributes little to the thrombotic tendency of primary APS whereas plasma HC may influence age at first event and number of events.
|
11734671 |
2001 |